Education
About Us
Working with TipRanks
Follow Us
Carmell Therapeutics Corporation (CTCX)
NASDAQ:CTCX
Total Valuation
Carmell Therapeutics has a market cap or net worth of $9.64M. The enterprise value is ―.
Market Cap$9.64M
Enterprise Value―
Share Statistics
Carmell Therapeutics has 30,119,843 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding30,119,843
Owned by Insiders16.39%
Owned by Institutions2.01%
Financial Efficiency
Carmell Therapeutics’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -18.50%.
Return on Equity (ROE)-0.62
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-18.50%
Return on Capital Employed (ROCE)-0.21
Revenue Per Employee0.00
Profits Per Employee-1.54M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Carmell Therapeutics is -2.72. Carmell Therapeutics’s PEG ratio is >-0.01.
PE Ratio-2.72
PS Ratio137.49
PB Ratio-1.18
Price to Fair Value1.70
Price to FCF-2.38
Price to Operating Cash Flow-1.65
PEG Ratio>-0.01
Income Statement
In the last 12 months, Carmell Therapeutics had revenue of 0.00 and earned -15.45M in profits. Earnings per share was -1.46.
Revenue0.00
Gross Profit-124.79K
Operating Income-5.22M
Pretax Income-16.21M
Net Income-15.45M
EBITDA-15.19M
Earnings Per Share (EPS)-1.46
Cash Flow
In the last 12 months, operating cash flow was -2.91M and capital expenditures -4.00, giving a free cash flow of -2.91M billion.
Operating Cash Flow-2.91M
Free Cash Flow-2.91M
Free Cash Flow per Share-0.10
Dividends & Yields
Carmell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.66
52-Week Price Change-87.98%
50-Day Moving Average0.34
200-Day Moving Average0.69
Relative Strength Index (RSI)41.74
Average Volume (3m)232.88K
Important Dates
Carmell Therapeutics upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Carmell Therapeutics as a current ratio of 1.63, with Debt / Equity ratio of -19.23%
Current Ratio1.63
Quick Ratio1.63
Debt to Market Cap0.03
Net Debt to EBITDA0.05
Interest Coverage Ratio-5.87
Taxes
In the past 12 months, Carmell Therapeutics has paid -760.16K in taxes.
Income Tax-760.16K
Effective Tax Rate0.05
Enterprise Valuation
Carmell Therapeutics EV to EBITDA ratio is -2.71, with an EV/FCF ratio of -4.92.
EV to Sales0.00
EV to EBITDA-2.71
EV to Free Cash Flow-4.92
EV to Operating Cash Flow-4.94
Balance Sheet
Carmell Therapeutics has $1.14M in cash and marketable securities with $781.70K in debt, giving a net cash position of -$355.62K billion.
Cash & Marketable Securities$1.14M
Total Debt$781.70K
Net Cash-$355.62K
Net Cash Per Share-$0.01
Tangible Book Value Per Share$2.24
Margins
Gross margin is 101.70%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin101.70%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Carmell Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―